Consistent with these effects, GLP-1 RAs have been associated with substantial weight loss in clinical trials, leading to FDA approval of two of these agents liraglutide and semaglutide for chronic weight management in adults with obesity or with overweight and at least one weight-related comorbidity
doi: 10.1002/ca.21011 28 GutierrezRSimonSA
However, head-to-head comparisons are limited, and individual patient responses vary considerably
Many of them dont just target the GLP-1 hormone, but go beyond this
The Pro version is typically distributed through healthcare providers and specialty pharmacies, and it shares the same core formulation but is positioned for clinical recommendations
Common side effects include nausea, vomiting, and constipation